 -The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union EU, addressing an urgent unmet medical need - In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL1,2,3 PLANEGGMUNICH, GERMANY and WILMINGTON, DE ACCESSWIRE August 26, 2021 MorphoSys AG FSE:MOR; NASDAQ:MOR and Incyte INCY today announced that the European Commission EC has granted conditional marketing authorization for Minjuvi tafasitamab in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL who are not eligible for autologous stem cell transplant ASCT. The EC Decision follows the positive opinion received from the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP in June 2021 recommending the conditional marketing authorization of Minjuvi. 